Ratings by Lucid Capital Markets (Elemer Piros)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/15/2026 | Adial Pharmaceuticals Inc | ADIL | New Coverage | Buy (N/A) |
2.98 (2.71) |
-9.06% | Details | |
| 5/13/2026 | NRX Pharma | NXRP | New Coverage | Buy (N/A) |
0.00 () |
0% | Details | |
| 4/27/2026 | XOMA Royalty Corp | XOMA | Downgrade | Neutral (Buy) |
37.90 (42.00) |
10.82% | Details | |
| 4/20/2026 | Passage Bio Inc. | PASG | Downgrade | Neutral (Buy) |
11.67 (5.72) |
-50.99% | Details | |
| 4/15/2026 | NervGen Pharma Corp | NGEN | New Coverage | Buy (N/A) |
4.19 (2.14) |
-48.93% | Details | |
| 3/11/2026 | INmune Bio Inc. | INMB | Upgrade | Buy (Neutral) |
1.28 (1.43) |
11.72% | Details | |
| 1/30/2026 | Quince Therapeutics Inc. | QNCX | Downgrade | Sell (Buy) |
0.27 (0.93) |
244.44% | Details | |
| 12/17/2025 | VistaGen Therapeutics | VTGN | Downgrade | Neutral (Buy) |
4.36 (0.64) |
-85.32% | Details | |
| 12/9/2025 | XOMA, Ltd. | XOMA | New Coverage | Buy (N/A) |
30.49 (37.90) |
24.3% | Details | |
| 11/24/2025 | Passage Bio Inc. | PASG | New Coverage | Buy (N/A) |
7.74 (11.67) |
50.78% | Details | |
| 11/12/2025 | Unicycive Therapeutics | UNCY | Maintain | Buy (N/A) |
|
Details | ||
| 10/21/2025 | Neuphoria Therapeutics Inc. | NEUP | Downgrade | Neutral (Buy) |
15.40 (4.44) |
-71.17% | Details | |
| 10/6/2025 | Cassava Sciences | SAVA | New Coverage | Buy (N/A) |
3.63 (2.38) |
-34.44% | Details | |
| 10/6/2025 | Cassava Sciences | SAVA | New Coverage | Buy (N/A) |
3.63 (3.63) |
0% | Details | |
| 9/30/2025 | Ocugen, Inc. | OCGN | New Coverage | Buy (N/A) |
1.45 (1.29) |
-11.03% | Details | |
| 9/22/2025 | Coya Therapeutics | COYA | Maintain | Buy (N/A) |
|
Details | ||
| 8/13/2025 | Ovid Therapeutics Inc | OVID | New Coverage | Buy (N/A) |
0.55 (2.25) |
309.09% | Details | |
| 7/31/2025 | OKYO Pharma Ltd. | OKYO | New Coverage | Buy (N/A) |
2.51 (1.57) |
-37.45% | Details | |
| 7/22/2025 | Tiziana Life Sciences | TLSA | New Coverage | Buy (N/A) |
1.62 (1.15) |
-29.01% | Details | |
| 7/1/2025 | INmune Bio Inc. | INMB | Downgrade | Neutral (Buy) |
5.33 (1.28) |
-75.98% | Details | |
| 6/6/2025 | Cybin Inc. | CYBN | New Coverage | Buy (N/A) |
8.82 (8.28) |
-6.12% | Details | |
| 6/6/2025 | atai Life Sciences N.V | ATAI | New Coverage | Buy (N/A) |
2.48 (4.05) |
63.31% | Details | |
| 6/4/2025 | Unicycive Therapeutics | UNCY | New Coverage | Buy (N/A) |
0.76 (7.87) |
935.53% | Details | |
| 6/4/2025 | INmune Bio Inc. | INMB | New Coverage | Buy (N/A) |
7.27 (5.33) |
-26.69% | Details |
